270 related articles for article (PubMed ID: 29089725)
1. Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.
Hutcherson TC; Cieri-Hutcherson NE; Bhatt R
P T; 2017 Nov; 42(11):692-698. PubMed ID: 29089725
[TBL] [Abstract][Full Text] [Related]
2. Idarucizumab: A Review as a Reversal Agent for Dabigatran.
Syed YY
Am J Cardiovasc Drugs; 2016 Aug; 16(4):297-304. PubMed ID: 27388764
[TBL] [Abstract][Full Text] [Related]
3. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
[TBL] [Abstract][Full Text] [Related]
4. [More safe anticoagulant treatment - use of idarucizumab (Praxbind®): case reports from RE-VERSE AD study and clinical practice].
Tuček D; Veleta T; Havrda M
Vnitr Lek; 2018; 64(3):309-313. PubMed ID: 29766734
[TBL] [Abstract][Full Text] [Related]
5. Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.
Van der Wall SJ; Lopes RD; Aisenberg J; Reilly P; van Ryn J; Glund S; Elsaesser A; Klok FA; Pollack CV; Huisman MV
Circulation; 2019 Feb; 139(6):748-756. PubMed ID: 30586692
[TBL] [Abstract][Full Text] [Related]
6. Idarucizumab (PRAXBIND®) as a sole reversal agent in an unstable hemorrhagic shock patient on an unknown anticoagulant with elevated protime/international normalized ratio (PT/INR).
Kutner S; Scaturo N; Williams B
Am J Emerg Med; 2021 Aug; 46():800.e1-800.e3. PubMed ID: 33612323
[TBL] [Abstract][Full Text] [Related]
7. Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran.
Brennan Y; Favaloro EJ; Pasalic L; Keenan H; Curnow J
Intern Med J; 2019 Jan; 49(1):59-65. PubMed ID: 29869387
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study.
Levy JH; van Ryn J; Sellke FW; Reilly PA; Elsaesser A; Glund S; Kreuzer J; Weitz JI; Pollack CV
Ann Surg; 2021 Sep; 274(3):e204-e211. PubMed ID: 31599808
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
[TBL] [Abstract][Full Text] [Related]
10. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
Thibault N; Morrill AM; Willett KC
Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
[TBL] [Abstract][Full Text] [Related]
11. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
Pollack CV; Reilly PA; Bernstein R; Dubiel R; Eikelboom J; Glund S; Huisman MV; Hylek E; Kam CW; Kamphuisen PW; Kreuzer J; Levy JH; Sellke F; Stangier J; Steiner T; Wang B; Weitz JI
Thromb Haemost; 2015 Jul; 114(1):198-205. PubMed ID: 26020620
[TBL] [Abstract][Full Text] [Related]
12. The Use of Idarucizumab for Dabigatran Reversal in Clinical Practice: A Case Series.
Goriacko P; Yaghdjian V; Koleilat I; Sinnett M; Shukla H
P T; 2017 Nov; 42(11):699-703. PubMed ID: 29089726
[TBL] [Abstract][Full Text] [Related]
13. Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran.
Giannandrea D; Mengoni A; Carluccio E; Ambrosio G
Vasc Health Risk Manag; 2019; 15():139-142. PubMed ID: 31213821
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials.
Dai JW; Wang CH; Chu CL; Liao SC
Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241113
[No Abstract] [Full Text] [Related]
15. Idarucizumab for Reversal of Dabigatran-Associated Bleeding: Misnomer or Miracle?
Miller L; Ferreira JA; Tucker C
J Emerg Med; 2017 Mar; 52(3):341-347. PubMed ID: 27727040
[TBL] [Abstract][Full Text] [Related]
16. Idarucizumab (Praxbind
Kalmanovich E; Battistella P; Rouviere P; Albat B; Frapier JM; Demaria R; Huet F; Agullo A; Mourad M; Colson P; Leclercq F; Gaudard P; Roubille F
Future Sci OA; 2021 Feb; 7(4):FSO689. PubMed ID: 33815827
[TBL] [Abstract][Full Text] [Related]
17. Extensive spontaneous cervical epidural hematoma due to oral anticoagulant (dabigatran) successfully treated with reversal agent idarucizumab alone.
Uddin SA; Roma K; Ross L; Hanna G; Drazin D; Kim TT
Surg Neurol Int; 2022; 13():259. PubMed ID: 35855155
[TBL] [Abstract][Full Text] [Related]
18. Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures.
Vornicu O; Larock AS; Dincq AS; Douxfils J; Dogné JM; Mullier F; Lessire S
Expert Opin Biol Ther; 2017 Oct; 17(10):1275-1296. PubMed ID: 28728489
[TBL] [Abstract][Full Text] [Related]
19. Idarucizumab: First Global Approval.
Burness CB
Drugs; 2015 Dec; 75(18):2155-61. PubMed ID: 26578027
[TBL] [Abstract][Full Text] [Related]
20. Idarucizumab for Dabigatran Reversal.
Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
